Table 5. Predictors of non-responders after intravitreal aflibercept therapy for treatment-switched patients.
|
BCVA |
Fundus finding |
|||||
|---|---|---|---|---|---|---|
| p value | OR | 95%CI | p value | OR | 95%CI | |
| BCVA | 0.844 | 1.233 | 0.154–9.837 | 0.131 | 0.071 | 0.002–2.202 |
| CCT | 0.542 | 1.004 | 0.992–1.016 | 0.987 | 1.000 | 0.984–1.014 |
| AMD type | ||||||
| tAMD | 0.305 | 2.174 | 0.493–9.585 | 0.739 | 0.756 | 0.146–3.921 |
| PCV | 0.559 | 0.127 | 0.127–2.463 | 0.664 | 1.444 | 0.275–7.586 |
| Type 1 NCV | 0.504 | 0.626 | 0.158–2.480 | 0.769 | 0.783 | 0.153–4.004 |
| Fundus findings | ||||||
| serous PED (>2DD) | 0.031* | 5.143 | 1.159–22.82 | 0.021* | 10.466 | 1.415–77.42 |
| fibrovascular PED (>3DD) | 0.465 | 0.433 | 0.046–4.097 | 0.028* | 13.36 | 1.328–134.4 |
| subretinal fluid | 0.999 | 0.000 | 0.407 | 0.451 | 0.069–2.959 | |
| macular edema | 0.207 | 0.237 | 0.025–2.224 | 0.998 | 0.000 | |
| retinal hemorrhage | 0.661 | 0.610 | 0.067–5.574 | 0.714 | 1.581 | 0.137–18.26 |
Multivariable logistic regression analyses adjusted for age, gender, CRT, and GLD at the time of initial IVA. Serous PED > 2 DD and fibrovascular PED > 3 DD were included. *p < 0.05.
BCVA, best corrected visual acuity; CCT, central choroidal thickness; AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; CNV, choroidal neovascularization; PED, pigment epithelial detachment; CRT, central retinal thickness; GLD, greatest linear dimension.